Stocks · News reference
U.S. stocks climbed, led by Dow’s 600-point gain; services PMI strengthened, Snowflake surged, while Ultragenyx plunged 44%.
Reference Details
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
Keep reading
The UK Medicines and Healthcare products Regulatory Agency (MHRA) has accepted the Marketing Authorisation Application for Ultragenyx's investigational gene therapy, rebisufligene etisparvovec, for the treatment of MPS IIIA.
Ultragenyx announced that the UK Medicines and Healthcare Products Regulatory Agency (MHRA) accepted its Marketing Authorisation Application for rebisufligene etisparvovec (UX111), an investigational gene therapy for MPS IIIA (Sanfilippo syndrome Type A). The company has also coordinated with NICE to align the evaluation timeline with the regulatory review process. The therapy received FDA approval in September 2026 and is also under review by the European Medicines Agency.
A Snowflake insider has sold company shares valued at approximately $3.06 million, according to a recent filing with the U.S. Securities and Exchange Commission.
Snowflake officer Dageville Benoit filed a Form 144 to sell 50,000 shares of common stock.
Ultragenyx announced the discontinuation of its GTX-102 Angelman syndrome program and its UX701 Wilson disease program following unsuccessful clinical trial results.